Comparative effects of rosuvastatin and allopurinol on circulating levels of matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with chronic heart failure

International Journal of Cardiology

Volumn 145, Issue 3, 2010, Pages 438-443

  Tousoulis, Dimitris ^a   Andreou, Ioannis ^a   Tentolouris, Costas ^a   Antoniades, Charalambos ^a   Papageorgiou, Nikolaos ^a   Gounari, Panagiota ^a   Kotrogiannis, Iason ^a   Miliou, Antigoni ^a   Charakida, Marietta ^a   Trikas, Athanasios ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Allopurinol; Heart failure; Metalloproteinases; Statins

Indexed keywords

ALLOPURINOL; GELATINASE A; GELATINASE B; INTERLEUKIN 1BETA; INTERLEUKIN 6; ROSUVASTATIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FAILURE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY;

AGED; ALLOPURINOL; BIOLOGICAL MARKERS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; EXTRACELLULAR MATRIX; FEMALE; FLUOROBENZENES; FREE RADICAL SCAVENGERS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2;

EID: 78649941703     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2009.05.051     Document Type: Article

References (34)

1. F.G. Spinale Matrix metalloproteinases: regulation and dysregulation in the failing heart Circ Res 90 2002 520 530
2. Y.Y. Li, A.M. Feldman, Y. Sun, and C.F. McTiernan Differential expression of tissue inhibitors of metalloproteinases in the failing human heart Circulation 98 1998 1728 1734
3. A. Vianello, L. Caponi, and F. Franzoni Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart Clin Sci (Lond) Feb 5 2009 [Electronic publication ahead of print]
4. J. Hansson, L. Lind, J. Hulthe, and J. Sundström Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study Eur J Cardiovasc Prev Rehabil. Apr 21 2009 [Electronic publicaftion ahead of print]
5. E.E. Creemers, J.P. Cleutjens, J.F. Smits, and M.J. Daemen Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 89 2001 201 210
6. J. George, S. Patal, D. Wexler, A. Roth, D. Sheps, and G. Keren Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure Am Heart J 150 2005 484 487
7. J.T. Peterson, H. Hallak, and L. Johnson Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure Circulation 103 2001 2303 2309
8. U. Landmesser, N. Engberding, and F.H. Bahlmann Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase Circulation 110 2004 1933 1939
9. K. Node, M. Fujita, M. Kitakaze, M. Hori, and J.K. Liao Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy Circulation 108 2003 839 843
10. S. Sola, M.Q. Mir, S. Lerakis, N. Tandon, and B.V. Khan Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure J Am Coll Cardiol 47 2006 332 337
11. L.B. Stull, M.K. Leppo, L. Szweda, W.D. Gao, and E. Marban Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy Circ Res 95 2004 1005 1011
12. N. Engberding, S. Spiekermann, and A. Schaefer Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation 110 2004 2175 2179
13. F.G. Spinale, M.L. Coker, and L.J. Heung A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
14. T. Yamazaki, J.D. Lee, H. Shimizu, H. Uzui, and T. Ueda Circulating matrix metalloproteinase-2 is elevated in patients with congestive heart failure Eur J Heart Fail 6 2004 41 45
15. E.M. Wilson, H.R. Gunasinghe, and M.L. Coker Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure J Card Fail 8 2002 390 398
16. H. Matsusaka, T. Ide, and S. Matsushima Targeted deletion of matrix metalloproteinase 2 ameliorates myocardial remodeling in mice with chronic pressure overload Hypertension 47 2006 711 717
17. F.G. Spinale, M.L. Coker, and S.R. Krombach Matrix metalloproteinase inhibition during the development of congestive heart failure: effects on left ventricular dimensions and function Circ Res 85 1999 364 376
18. G.W. Moe, G. Laurent, L. Doumanovskaia, A. Konig, X. Hu, and P. Dorian Matrix metalloproteinase inhibition attenuates atrial remodeling and vulnerability to atrial fibrillation in a canine model of heart failure J Card Fail 14 2008 768 776
19. Y.Y. Li, C.F. McTiernan, and A.M. Feldman Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling Cardiovasc Res 46 2000 214 224
20. D. Tousoulis, M. Charakida, E. Stefanadi, G. Siasos, G. Latsios, and C. Stefanadis Statins in heart failure. Beyond the lipid lowering effect Int J Cardiol 115 2007 144 150 (Pubitemid 46136536)
21. J. Bauersachs, P. Galuppo, D. Fraccarollo, M. Christ, and G. Ertl Improvement of left ventricular remodeling and function by hydroxymethylglutaryl coenzyme A reductase inhibition with cerivastatin in rats with heart failure after myocardial infarction Circulation 104 2001 982 985
22. S. Bellosta, D. Via, and M. Canavesi HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages Arterioscler Thromb Vasc Biol 18 1998 1671 1678
23. S. Hayashidani, H. Tsutsui, and T. Shiomi Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction Circulation 105 2002 868 873 (Pubitemid 34174929)
24. S. Ichihara, A. Noda, and K. Nagata Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure Cardiovasc Res 69 2006 726 735
25. V. Zaca, S. Rastogi, and M. Imai Chronic monotherapy with rosuvastatin prevents progressive left ventricular dysfunction and remodeling in dogs with heart failure J Am Coll Cardiol 50 2007 551 557 (Pubitemid 47126770)
26. H. Krum, E. Ashton, and C. Reid Double-blind, randomized, placebo-controlled study of high-dose HMG CoA reductase inhibitor therapy on ventricular remodeling, pro-inflammatory cytokines and neurohormonal parameters in patients with chronic systolic heart failure J Card Fail 13 2007 1 7
27. A. Radauceanu, C. Ducki, and J.M. Virion Extracellular matrix turnover and inflammatory markers independently predict functional status and outcome in chronic heart failure J Card Fail 14 2008 467 474
28. M.V. Gurjar, R.V. Sharma, and R.C. Bhalla eNOS gene transfer inhibits smooth muscle cell migration and MMP-2 and MMP-9 activity Arterioscler Thromb Vasc Biol 19 1999 2871 2877
29. V. Mellin, M. Isabelle, and A. Oudot Transient reduction in myocardial free oxygen radical levels is involved in the improved cardiac function and structure after long-term allopurinol treatment initiated in established chronic heart failure Eur Heart J 26 2005 1544 1550
30. K.M. Minhas, R.M. Saraiva, and K.H. Schuleri Xanthine oxidoreductase inhibition causes reverse remodeling in rats with dilated cardiomyopathy Circ Res 98 2006 271 279
31. J. Kjekshus, E. Apetrei, and V. Barrios Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
32. The GISSI-HF Investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
33. J.G.F. Cleland, P. Dunselman, and A. Hjalmarson on behalf of the CORONA study group. Interaction between the effects of rosuvastatin and plasma concentrations of NT-proBNP, a post-hoc exploratory analysis from the CORONA study Eur Heart J 29, Suppl 1 2008 134
34. A.J. Coats Ethical authorship and publishing Int J Cardiol 131 2009 149 150